a r t i c l e s HIV type 1 (HIV-1) uses multiple mechanisms to evade the immune system, and these have stymied the development of an effective vaccine [1] [2] [3] . One mechanism-conformational masking 4 -hides the vulnerable shape of the trimeric envelope (Env) recognized by broadly neutralizing antibodies via structural rearrangements that expose immunodominant epitopes recognized by non-neutralizing or poorly neutralizing ('ineffective') antibodies 5, 6 . The upshot is that virus infection and Env immunization both elicit abundant production of Env-directed antibodies with little neutralization capacity [7] [8] [9] . A potential solution is to determine the structure of the vulnerable Env conformation and to use this structural information and protein design to stabilize or to fix the vulnerable shape.
a r t i c l e s HIV type 1 (HIV-1) uses multiple mechanisms to evade the immune system, and these have stymied the development of an effective vaccine [1] [2] [3] . One mechanism-conformational masking 4 -hides the vulnerable shape of the trimeric envelope (Env) recognized by broadly neutralizing antibodies via structural rearrangements that expose immunodominant epitopes recognized by non-neutralizing or poorly neutralizing ('ineffective') antibodies 5, 6 . The upshot is that virus infection and Env immunization both elicit abundant production of Env-directed antibodies with little neutralization capacity [7] [8] [9] . A potential solution is to determine the structure of the vulnerable Env conformation and to use this structural information and protein design to stabilize or to fix the vulnerable shape.
Definition of the structure of trimeric HIV-1 Env has been accomplished at increasing resolution by crystallography and cryo-EM [10] [11] [12] [13] [14] .
These studies have culminated in atomic-level structures of antibody-bound forms of a near-native trimer mimic, named BG505 SOSIP.664, for HIV-1 strain (BG505) 15 and stabilizing mutations (SOSIP.664) [16] [17] [18] . However, bound antibodies can influence conformation. Structures of the Env gp120 subunit, for example, can differ substantially when ligand free 19 or when bound to different antibodies 3, 6, [20] [21] [22] [23] [24] . HIV-1 Env, moreover, is a type 1 fusion machine, which uses structural rearrangements to drive the merging of virus and host-cell membranes during entry (reviewed in ref. 25) . Substantial prefusion-to-postfusion conformational changes accompany this process 14, 26, 27 , and single-molecule fluorescence resonance transfer (smFRET) analysis has indicated that prefusion ligand-free Env on infectious virions undergoes transitions among at least three different conformations 28 .
When a viral antigen can assume multiple conformations, which is the 'right' conformation to fix? Clues from smFRET 28 and hydrogen/ deuterium exchange (HDX) experiments 29 have suggested that a single dominant conformation, the mature prefusion closed state, is recognized by broadly neutralizing antibodies. Here we set out not only to fix HIV-1 Env in its vulnerable shape but also to determine the appropriate conformation to fix. We layered antigenic considerations-for both structure and binding-onto structure-based design. To provide a basis for the analysis, we determined the crystal structure of the ligandfree HIV-1-Env trimer and analyzed its structural compatibility with epitopes defined in previously determined antibody-bound Env structures. We coupled structural compatibility with binding measurements to identify both an 'appropriate target conformation' and an 'appropriate target antigenicity' and used antigenicity-guided structural design to fix the desired target shape. We then examined the functional and antigenic consequences of conformational fixation. Functional analysis revealed that HIV-1 Env transitions through an asymmetric intermediate, and antigenic analysis indicated improved specificity for broadly neutralizing antibodies. Together, our results provide a foundation by which to understand ligand-free HIV-1-Env trimer: its structure, its entry-related mechanistic interactions and its conformational fixation as a means to overcome conformational masking.
RESULTS

Structure and properties of ligand-free HIV-1-Env trimer
To obtain the structure of mature ligand-free HIV-1 Env, we used a sparse-matrix approach 30 to crystallize an endoglycosidase H-treated BG505 SOSIP.664 trimer from a PEG 400-PEG 3350 precipitant mixture 31 . Diffraction data extended to 3.3 Å but were anisotropic with a nominal resolution of 3.7 Å ( Table 1) . Because of the lower resolution, we were careful with crystallographic B factors; refinement without B factors did not reduce R free to below 33%, whereas refinement 32 with group B factor and translation-libration-screw motions yielded R work /R free of 26.6%/28.5% (Fig. 1, Table 1 and Supplementary  Figs. 1 and 2) . The resulting B factors correlated strongly with real-space correlation (Supplementary Table 1) , thus suggesting a reflection of prefusion coordinate mobility.
To provide insight into the physical characteristics of ligand-free HIV-1 Env, we analyzed residue and surface properties including sequence entropy, atomic mobility, hydrophobicity, polarity and surface accessibility ( Fig. 1 and Supplementary Figs. 1 and 2 ). Of these, Cα differences between separate subunit structures and the ligand-free trimer showed moderate correlation with B factors (Supplementary Tables 1 and 2 ). When only the gp41 subunit was considered, the correlation increased (P <0.0001; Fig. 1b) . Thus, gp41 regions of ligand-free trimeric Env that are structurally similar in the separate subunit context exhibit lower B factors, increased hydrophobicity, reduced surface accessibility and reduced sequence variation: these regions include the nascent α7 coiled coil, which underpins the internal coiled coil of the postfusion six-helix bundle. In contrast, Supplementary Fig. 3 ). P values in b and c were obtained by two-tailed Student's t test (n defined in Supplementary Fig. 3 ).
a r t i c l e s npg a r t i c l e s gp41 regions that differ in the separate subunit context, such as the α8 and α9 helices, displayed higher B factors, increased polarity and higher surface accessibility in the prefusion closed state. One explanation for these results is that gp41 residue-level properties associated with prefusion mobility presage or predict regions that move between prefusion and postfusion states. Indeed, prefusion B factors correlated strongly with gp41 movement between prefusion and postfusion states (Fig. 1c) . Relevant to this, we also observed that prefusion B factors of the fusion subunit from influenza virus (HA2) and respiratory syncytial virus (F1) correlated with prefusion-to-postfusion movement ( Fig. 1c and Supplementary  Fig. 3 ). Thus, clues to viral entry-related conformational change can be found in the ligand-free prefusion structures of Env, with residues of the fusion subunits in these type 1 fusion machines Supplementary Fig. 5) . P values for Spearman correlations provided (n = 14 antibodies). npg a r t i c l e s poised on a mobility gradient to undergo the requisite conformational rearrangements required for entry.
Structural compatibility and appropriate target conformation
In addition to facilitating virus entry, HIV-1 Env functions to evade the humoral immune response, a function in which glycan shielding and conformational change are critical. In the refined ligand-free Env structure, we observed electron density corresponding to single protein-proximal N-acetyl glucosamine residues at all sites of N-linked glycosylation, except at residues 197, 262 and 332 (with Env numbering following standard HXB2 convention) 33 , for which we observed additional monosaccharide residues, or at residue 137, which was mostly disordered (Supplementary Fig. 4) . Overall, despite differences in glycosylation and lattice packing ( Supplementary Fig. 4) , the structure of the ligand-free trimer assumed a closed conformation, which was highly similar to that of antibody-bound trimers [12] [13] [14] , especially the PGT122-35O22-bound trimer 14 , with which it had an r.m.s. deviation in Cα positions of less than 1 Å, substantially lower than observed with monomeric gp120 (Fig. 2a) .
To determine the appropriateness of the ligand-free closed trimer as a vaccine template, i.e., structural specificity for broadly neutralizing antibodies and incompatibility with non-neutralizing or poorly neutralizing antibodies, we first sought to categorize antibodies according to their functional efficacy (Fig. 2b) . We defined broadly neutralizing antibodies as those with greater than 35% breadth on a diverse panel of 170 isolates and defined ineffective antibodies as those with less than 15% breadth. (For an isolate to be considered sensitive in this breadth analysis, we used a cutoff for antibody half-maximal inhibitory concentration (IC 50 ) of <50 µg/ml). Antibodies b12 (ref. 34) , 35O22 (ref. 35 ) and PGT135 (ref. 36 ) were close to the cutoff for the broadly neutralizing category. Some antibodies showed clade-specific breadth, for example, V3-directed 447-52D 37 , which neutralizes over 20% of clade B isolates. However, we nonetheless classified 447-52D as ineffective because its overall breadth was only 12% (Supplementary Table 3 ). We then analyzed the ligand-free closed structure for its structural compatibility with antibody epitopes-most determined structurally in the context of antibody-bound subunit or antibodybound peptide-on the basis of two measures: antibody-volume overlap and epitope r.m.s. deviation ( Fig. 2c and Supplementary Fig. 5 ). Antibody-volume overlap, which involves the superposition of epitopes in the ligand-free trimer and the antibody-bound context ( Supplementary Fig. 5 ), was strongly anticorrelated with neutralization breadth (P = 0.0007; Fig. 2d ). Epitope r.m.s. deviation, which compares epitope structural differences in the ligand-free trimer and the antibody-bound context, varied with breadth but did not achieve statistical significance. An antigenic structural-compatibility score (ASC), which combined both overlap and r.m.s. deviation, did achieve significance (P = 0.0031; Fig. 2d ).
The ligand-free closed structure was compatible with the epitopes for all broadly neutralizing antibodies, except those of the membraneproximal external region, which recognize epitopes C terminal to residue 664, and those of antibodies b12 (ref. 21 ) and CH103 (ref. 38) , with CH103 exceeding a 2-Å threshold of epitope similarity and b12 exceeding a volume threshold of 500 Å 3 (Fig. 2d) . In light of the poor correlation of epitope r.m.s. deviation with neutralization breadth (Fig. 2d) , the r.m.s. deviation threshold was somewhat arbitrary. Nonetheless, the specific incompatibility of these moderately effective CD4-binding-site antibodies suggests that movement of residues of the CD4-binding site could occur relative to the ligand-free closed trimer; indeed, induced trimer movements have been observed for b12 (which binds poorly to the BG505 SOSIP.664 trimer 18 ) by EM 10 and HDX 29 . By contrast, none of the epitopes for non-neutralizing or poorly neutralizing antibodies were structurally compatible with the ligand-free closed structure (Fig. 2d) . These results indicate that the ligand-free closed trimer is structurally specific for neutralizing antibodies and thus is in an appropriate target conformation for immunogen design.
Appropriate target antigenicity for an Env-vaccine antigen
Structural specificity, as measured by epitope compatibility, is only one of the requirements of an appropriate vaccine template, and antigenic specificity, as measured by antibody binding, is also crucial. 
npg a r t i c l e s
The BG505 SOSIP.664 has previously been shown to be antigenically specific for broadly neutralizing antibodies, though binding to weakly neutralizing antibodies such as those directed to the V3 loop has been reported 18 .
Our structural-compatibility analysis indicated that V3 antibodies are incompatible with the ligand-free closed state (Fig. 2c) , suggesting that the binding of BG505 SOSIP.664 to V3 antibodies might not be intrinsic to the closed conformation of the SOSIP.664 construct but may instead be an artifact of alternative folding. Indeed, we found that negative selection 39 by weakly neutralizing V3-directed antibodies substantially reduced V3 antibody binding to BG505 SOSIP.664 ( Fig. 3a and Supplementary Data Set 1) ; when we tested recognition on a panel of V3-directed antibodies, negative selection by 447-52D and by a V3-antibody cocktail reduced recognition by V3-directed antibodies to a level similar to that observed for noncognate antibody binding (Fig. 3b,c) . We also tested CD4-negative selection but did not observe a substantial non-CD4-binding subportion of Env trimers. Together, these results indicated that an appropriate target antigenicity for an Env-vaccine antigen (Fig. 3d) would involve no recognition by ineffective antibodies (including those directed at the V3 region), while maintaining recognition of broadly neutralizing antibodies (except those with moderate neutralization, directed at the CD4-binding site).
CD4 triggering and conformational stabilization
Even after V3-antibody negative selection, CD4 triggering could efficiently expose V3 epitopes 40 , recognized by antibodies such as 447-52D 41 , 3074 (ref. 42 ) and others, as well as bridging-sheet epitopes 20 , recognized by antibodies such as 17b 43 (Fig. 4a and Supplementary Data Sets 2 and 3). Thus, although structural compatibility (and neutralization breadth) generally correlated with antibody binding, this correlation was lost in the presence of CD4 (Fig. 4a and Supplementary Data Set 2) . Notably, CD4 triggered BG505 SOSIP.664 recognition of ineffective antibodies so that their average binding was tighter than that of the broadly neutralizing ones (Fig. 4a) . Such CD4 triggering makes BG505 SOSIP.664 less desirable as an immunogen: in primates, it would bind CD4 in vivo and would thus be predicted to elicit production of primarily ineffective antibodies against highly immunogenic CD4-induced epitopes. 
a r t i c l e s
To fix the ligand-free closed state and to prevent CD4 triggering, we analyzed regions of the ligand-free closed structure that moved upon CD4 binding and identified cavity-filling hydrophobic substitutions, side chain pairs capable of forming disulfide bonds and positions where the introduction of a proline would be compatible with only the ligand-free closed structure of Env but not its receptor-bound conformation (Fig. 4b) . We engineered these substitutions into BG505 SOSIP.664, coexpressed them with furin in a 96-well transfection format 44 Table 4 ). We purified and analyzed promising constructs for gp120-gp41 cleavage and oligomeric heterogeneity (Supplementary Fig. 6 ) and used mesoscale-discovery electrochemiluminescence immunoassay (MSD-ECLIA) to determine recognition on a more comprehensive panel of HIV-1-reactive antibodies (Fig. 4c, Supplementary Data Set 2 and Supplementary Tables 5 and 6). One cavity-filling alteration, Y191W, was recognized by broadly neutralizing antibodies but exhibited only moderately reduced binding by antibody 17b, whereas two proline substitutions, Q432P and A433P, showed improved antigenic specificity. A 201C 433C double-cysteine mutant showed virtually no recognition by antibody 17b, even in the presence of CD4, but it was recognized equivalently to SOSIP.664 by antibody PGT145 and was bound even better by antibody CAP256-VRC26.09 (Fig. 4c) . Although Modeling indicated that a 201C 433C disulfide is incompatible with the CD4-bound state, in which the Cαs of residues 201 and 433 are 9.4 Å apart, separated by a strand of the bridging sheet 20 , and the V3 loop is fully exposed 6 (Fig. 5a) . By contrast, the 201C 433C substitutions are expected to form a disulfide in the ligand-free closed trimer, and indeed the ligand-free BG505 SOSIP.664 201C 433C exhibited a 6.1 °C increase in thermostability (to 73.1 °C), relative to that of the parent SOSIP.664 (Fig. 5b) , as well as increased tolerance to other physical stresses such as pH and freeze-thaw (Fig. 5c) . These results indicated that the 201C 433C DS variant of BG505 SOSIP.664 (herein named DS-SOSIP.664) is conformationally stabilized and is not triggered by CD4.
CD4 interaction of DS-stabilized HIV-1 Env
To define the interaction of the ligand-free conformation of DS-SOSIP.664 with CD4, we used surface plasmon resonance (SPR) (Fig. 6a) . DS-SOSIP.664 recognized CD4 with a similar on rate as that of the parent SOSIP.664 but with an off rate approximately ten-fold faster, which resulted in an approximately ten-fold reduction in K d relative to that of SOSIP.664 (Fig. 6a) . To test for CD4 triggering over a longer time scale, we incubated both DS-SOSIP.664 and parent SOSIP.664 for 100 h in the presence of CD4 and used SPR readout of antibody 17b or antibody 3074 to assess triggering. With the parent SOSIP.664, CD4 induced a slow transition to a state with the bridging sheet formed (time for half-maximal binding (t 1/2 ) of 3.3 ± 0.7 h (s.e.) for antibody 17b 43 ) and the V3 loop exposed (t 1/2 of 4.2 ± 1.0 h for antibody 3074 (ref. 42)) ( Fig. 6b and Supplementary Data Set 3d) . With DS-SOSIP.664, we could not observe triggering by CD4 of the bridging sheet or V3 regions over the entire 100-h time course (Fig. 6b and Supplementary Data Set 3d) .
To define the stoichiometry of CD4 interaction, we used sedimentation equilibrium analytical ultracentrifugation of parent and DS-SOSIP.664 variants in the presence of excess CD4. With both two-domain CD4 (Fig. 6c) and four-domain CD4 (Supplementary Data Set 4), we observed molecular weights consistent with that of the parent SOSIP.664 binding two to three CD4s and DS-SOSIP.664 binding only one CD4. DS-SOSIP.664 thus appeared to capture Env in a single-CD4-bound state.
DS-stabilized HIV-1 Env in the viral context
Because the single-CD4-bound state could be SOSIP.664 specific, we sought to assess DS-stabilized Envs in other contexts. When we placed DS mutations into functional viruses, they ablated entry (Supplementary Data Set 5) . smFRET measurements, with donors and acceptors placed in the first and fourth variable Env loops of functional JR-FL viral spikes 28 , revealed that DS mutations reduce transitions from the ground state. DS viral spikes remained primarily in the closed ground state, even in the presence of dodecameric CD4 (ref. 48) (Fig. 7a) .
Overall, the asymmetric single-CD4-bound state-with fast off rate for CD4-appeared to be an obligatory intermediate between the ligand-free state and a more fully CD4-triggered state capable of binding multiple CD4s and co-receptor (Fig. 7b) . In this context, we note that the high off rate of CD4 in the single-CD4-bound state, coupled with the slow transition to a 3:1 CD4/trimer stoichiometry, provides a kinetics-based molecular mechanism for the ability of primary HIV-1 isolates to resist neutralization by monomeric CD4 (ref. 49) .
A new generation of DS-fixed HIV-1-Env trimeric antigens
The ligand-free Env trimer fixed in the prefusion closed conformation may be an ideal HIV-1 antigen. To obtain information on the mobility of DS-SOSIP in both ligand-free and CD4-bound states, we characterized a r t i c l e s the HDX of DS-SOSIP.664 and parent SOSIP.664 with and without CD4. Without CD4, the HDX of DS-SOSIP.664 appeared similar to that of the parent SOSIP.664 (Fig. 8a, Supplementary Fig. 7 and Supplementary Data Set 6); with CD4, the gp120 inner domain, the bridging sheet and gp41 showed little change (Fig. 8a) . The V2 and V3 and the stem of V1 showed a response to CD4 that was consistent with the slightly increased exposure of the V3 epitope observed by MSD-ECLIA (Fig. 4d) , but this was substantially less than that observed for the parent SOSIP.664 (Fig. 8a) . The CD4-bound DS-SOSIP.664 thus differs from previously observed CD4-bound states in that the typical hallmarks of CD4 induction, such as bridging-sheet formation and V3 exposure, are absent or substantially reduced.
To investigate whether the DS substitutions might serve as a general means of reducing CD4-induced transition in other Env antigens, we placed the 201C 433C and SOS mutations into HIV-1 Env expressed on the surface of enzyme-treated pseudovirions 50 . We chose two types of virions: (i) strain JR-FL, modified with E168K 51 , to allow binding of V1V2-directed broadly neutralizing antibodies and (ii) strain BG505, modified with T332N 18 , to allow binding of the 2G12 (ref. 52) antibody. We observed that DS-modified viral spikes resisted CD4 triggering and retained the antigenic profile of the soluble trimer for broadly neutralizing antibodies in both JR-FL and BG505 Env backgrounds (Fig. 8b) . Overall, the results indicate that the disulfide-shackled 201C 433C variants of soluble SOSIP.664 and VLP SOS are highly desirable antigens: conformationally fixed trimers in which neutralizing epitopes are almost exclusively exposed and non-neutralizing or poorly neutralizing epitopes are hidden, even in the presence of CD4.
DISCUSSION
The path to identifying the 201C 433C DS mutant involved an information flow starting with broadly neutralizing antibodies and moving to the ligand-free Env structure and then to an analysis of its structural compatibility and binding antigenicity; this allowed us to obtain conformationally fixed antigens of desired target antigenicity (Fig. 8c) . Such antigenicity-guided structural design may be generally applicable, and indeed an analogous design path was previously followed in the conformational stabilization of the fusion (F) glycoprotein from respiratory syncytial virus (RSV), which resulted in the production of high levels of RSV-neutralizing antibodies 44 . However, RSV F assumes primarily two conformations, prefusion 53 and postfusion 54, 55 , whereas HIV-1 Env can assume a multitude of conformations, including at least three prefusion states 28 and numerous conformations of separate gp120 and gp41 subunits. The conformational fixation of Env thus required analysis of antibody efficacy and antibody-induced conformation, and we formalized this with an in-depth analysis of structural compatibility. An understanding of the conformational complexity of Natural human antibody response to HIV segregated by neutralization efficacy (Fig. 2b) Antibody efficacy and structural compatibility of ligand-free Env mapped with antigenicity in the absence and presence of CD4 (Fig. 4a) Antigenicity-guided structural design (Fig. 4b,c) Antibody efficacy and structural compatibility of ligand-free Env mapped with antigenicity of DS-Env in the absence and presence of CD4 (Fig. 4d) Adaptation of conformational fixation into other immunogen platforms (Fig. 8b) Epitope structural compatibility of ligand-free Env mapped with antibody efficacy (Fig. 2c,d npg a r t i c l e s the HIV-1 Env, moreover, has the potential for mechanistic dividends: fixing the conformation of a particular Env entry intermediate-in this case, the ligand-free closed state-provided a means to define the mechanistic interactions of that particular state. Unexpectedly, analysis of the DS mutant indicated an asymmetric mechanism of entry, with CD4 binding separated into two steps (Fig. 7b) : first, recognition by one CD4 without the previously recognized antigenic hallmarks of CD4 binding such as bridging-sheet formation, and second, recognition by more than one CD4, along with exposure or formation of characteristic CD4-induced epitopes. The restricted stoichiometry of DS-SOSIP.664 is unlikely to be a consequence of steric hindrance of the binding of additional CD4 molecules by the first bound CD4; instead, the conformational change induced by the first CD4 apparently generates sufficient alterations of the Env trimer to impede the binding of a second CD4. In this context, we note that in SPR characterizations of CD4 induction (Fig. 6b) , we observed a Hill coefficient of 0.95 ± 0.10 for the P313W mutant, which is able to rapidly engage three CD4s, and a Hill coefficient of 0.69 ± 0.06 for SOSIP.664, which displayed a t 1/2 for CD4 induction of several hours, thus suggesting negative cooperativity in which the binding of one CD4 impedes the binding of additional CD4 molecules. Although similar asymmetric or restricted binding for CD4 has been reported with other trimeric HIV-1-Env constructs 56, 57 , none of these other reports found binding of a single CD4 without the typical antigenic hallmarks induced by CD4, such as bridging-sheet formation 20 . In general, we believe that the single-CD4-bound trimeric state of Env is not specific to DS-SOSIP.664 but instead is an obligatory intermediate of an asymmetric entry pathway (Fig. 7b) .
In addition to providing mechanistic insight into HIV-1 entry, antigenicity-guided conformational fixation can also improve the antigenic specificity of HIV-1-Env immunogens. We used the ligandfree HIV-1-Env trimer as a target structure because ligand-free immunogens are typically used for vaccination. In hindsight, we could have used the PGT122-35O22 antibody-bound trimer structure 14 because it is highly similar to the ligand-free structure; however, at the outset of the study, we anticipated this similarity only at the label-specific resolution of smFRET 28 . We nevertheless managed to achieve our goal: the creation of DS-Env antigens that were conformationally fixed in the vulnerable shape and were not recognized by ineffective antibodies (including those directed against V3) and were not triggered by CD4.
Even with conformational masking disabled, HIV-1 Env is additionally protected by immune evasion involving genetic variation and glycan shielding and would thus be protected by evasion mechanisms similar to those used by influenza virus hemagglutinin (Supplementary Fig. 8 ). Immunization with conformationally fixed HIV-1 Env might therefore be expected to elicit immunological responses similar to those elicited by the seasonal flu vaccine: strain-specific responses with little neutralization breadth. Indeed, this is what initial reports of immunization with BG505 SOSIP.664 have described 58 . Although an improvement over what is elicited by conformationally masked Env (for example, by gp120-subunit immunization), such strain-specific neutralization is unlikely to be generally protective. We note, however, that the immunogens in these initial reports exhibit V3-epitope exposure 18 , in contrast to the V3-negatively selected DS-SOSIP described here. As a result, DS-SOSIP might be expected to induce responses that are more focused on desirable neutralizing epitopes. Altogether, because the 201C 433C DS mutation provides a means to overcome conformational masking, it should provide the basis for a new generation of vaccine antigens; however, future efforts to elicit broad HIV-1-neutralizing antibodies may require additional immunogen engineering to overcome remaining neutralization-evading mechanisms of genetic variation and glycan shielding. 
METHODS
Methods
a r t i c l e s
Reprints and permissions information is available online at http://www.nature.com/ reprints/index.html.
ONLINE METHODS
BG505 SOSIP.664 expression, purification and deglycosylation. BG505 SSOIP.664 trimer was produced in HEK 293 GnTI −/− cells via transient transfection of the BG505 SOSIP-expressing plasmid with furin and purified as described previously, over a 2G12 affinity column 12, 14, 18 (additional details, including transient transfection in 96-well plates in Supplementary Note). The cell line was purchased from ATCC (cat. no. CRL-3022) and was authenticated and checked for mycoplasma contamination by the vendor. The eluted protein was then dialyzed against PBS and set for deglycosylation reaction at 37 °C in reaction buffer containing 1 mM EDTA, 150 mM NaCl, protease-inhibitor cocktail (Roche), 17,000 units of Endo H per ml and 50 mM sodium acetate, pH 5.8. The deglycosylated BG505 SOSIP was further purified with a Superdex 200 16/60 (GE Healthcare) column in buffer containing 5 mM HEPES, pH 7.5, 150 mM NaCl and 0.02% NaN 3 . The peak corresponding to trimeric HIV-1 Env was identified, pooled and concentrated to ~10 mg/ml with an Amicon Ultra-15 centrifugal filter (MWCO 50,000, Millipore) and screened for crystallization. Similarly purified 'crystallization-grade' samples were also used for HDX experiments.
For most antigenicity and stability analyses, after trimers were purified by affinity chromatography and gel filtration over a Superdex 200 16/60 (GE Healthcare) column in buffer containing 5 mM HEPES, pH 7.5, 150 mM NaCl and 0.02% NaN 3 , they were subjected to negative selection 39 . This generally involved a V3 antibody 447-52D (PDB 4M1D 61 ) affinity column to remove aberrant trimer species. However, for select antigenic analyses (for example, Fig. 4a,d 64 , respectively), was used (Fig. 3, Supplementary Data Set 1 and Supplementary Note).
Crystallization screening. Deglycosylated BG505 SOSIP.664 was screened for crystallization with 572 conditions in Hampton, Wizard and Precipitant Synergy 31 screens with a Cartesian Honeybee crystallization robot, as described previously 59 , and a mosquito robot with 0.1 µl of reservoir solution and 0.1 µl of protein solution. Crystals suitable for structural determination were obtained robotically in 26% PEG 400, 3.2% PEG 3350 and 0.1 M sodium acetate, pH 5.5. Crystals were cryoprotected in a solution containing 30% glycerol, 30% PEG 400, 4% PEG 3350 and 0.1 M sodium acetate, pH 5.5, and were flash frozen in liquid nitrogen. Data were collected at a wavelength of 1.00 Å at the SER-CAT beamline ID-22 (Advanced Photon Source, Argonne National Laboratory).
X-ray data collection, structure solution and model building. Diffraction data were processed with the HKL2000 suite 65 . The data were corrected for anisotropy with the anisotropy server http://services.mbi.ucla.edu/anisoscale/ with truncations to 3.7 Å, 3.7 Å and 3.3 Å along the a, b and c axes, respectively. Structural analyses involving residue-specific properties. To estimate the degree of structural flexibility in the ligand-free HIV-1 trimer, we determined the average Cα r.m.s. deviation distance for each residue position in the ligand-free trimer structure (Fig. 2d,e) . The average Cα r.m.s. deviation distance served as a proxy for structural plasticity and was computed between corresponding residues after optimal superimposition onto a set of 98 structures from the Protein Data Bank (PDB) 67 . Each domain of the ligand-free trimer was considered separately and superimposed onto the set of structures with either the program TM-align 68 or single-value decomposition (SVD). To obtain the correct registry between corresponding residues, structural superimpositions were guided by amino acid sequence alignments when necessary. A total of 63 monomeric structures were used for superimpositions involving the gp120 domain (Supplementary Table 2 ). To generate Figure 2a (left), we used five representative gp120 structures; ligand-free clade A/E HIV-1 gp120 core e (PDB 3TGT) 19 , b12-bound gp120 (PDB 2NY7) 21 , b13-bound gp120 (PB 3IDX) 3 , F105-bound gp120 (PB 3HI1) 3 and VRC01-bound gp120 (PDB 3NGB) 69 structures. For the gp41 domain, we used a total of 35 structures from the PDB that included hexameric bundles as well as disordered peptides (Supplementary Table 2) .
To understand the dynamic properties of ligand-free BG505 SOSIP.664, qualitative exchange profiles for observable peptides of SOSIP.664 after 3 s were extracted from individual HDX-MS exchange plots 70 . The average exchange values (0-75%) were substituted in the B-factor field for the observed peptides of closed, ligand-free BG505 SOSIP.664 coordinates and displayed within PyMOL (http://www.pymol.org/) (Supplementary Figs. 1g and 2g) . Peptides not observed in the deuterium-exchange experiment as well as peptides with missing electron density were excluded from the analysis.
Other residue-specific properties were calculated and are shown in Supplementary Table 1. These included residue depth 71 , solvent-accessible surface area (SASA) (NACCESS program; S. Hubbard and J. Thornton (University College London)), sequence variability and hydrophobicity. Residue sequence variability was computed as the Shannon entropy for each residue position on the basis of a representative set of 3,943 HIV-1 strains (Supplementary Figs. 1e  and 2e) . The electrostatic-potential surfaces were generated with GRASP 72 . The Pearson correlation coefficient and associated P values (computed with two-tailed t test) were computed with the statistical package R. Residue-level and surface property analyses were carried out with coordinates that differed slightly from those deposited in the PDB (r.m.s. deviation of the analyzed coordinates differed by 0.02 Å for regions compared, and B factors were identical).
Assessment of antibody-functionality on a panel of 170 diverse HIV-1 isolates.
Neutralization was measured with single-round-of-infection HIV-1-Env pseudoviruses and TZM-bl target cells, as described previously 73 . Neutralization curves were fit by nonlinear regression with a five-parameter Hill-slope equation. The 50% and 80% inhibitory concentrations (IC 50 and IC 80 ) were reported as the antibody concentrations required to inhibit infection by 50% and 80%, respectively. The following antibodies were tested for HIV-1 neutralization efficacy: 17b 20 Computation of antibody-epitope r.m.s. deviation, volume overlap and epitope presence. HIV-1-specific antibody-antigen complex structures were compiled from the PDB, and antibodies were defined as broadly or poorly/non neutralizing, according to published or in-house neutralization data of diverse viral strains 80 . Antibodies that were deemed to have insufficient evidence for being classified as broadly or poorly/non neutralizing were excluded from the analysis. A single antibody representative was included in the analysis in cases in which multiple antibody clonal relatives were found. The epitope residues for each antibody were defined on the basis of the respective antibody-antigen complex crystal structures, with an antigen residue being defined as an epitope residue if any of its heavy atoms were within 5.5 Å of any antibody heavy atom. To compute the r.m.s. deviation between the epitope residues in the antibody-antigen complex structure and the same residues in the ligand-free trimer structure, first the epitope residues from the complex structure were aligned to the ligand-free trimer structure with the align function in PyMOL, and then the Cα r.m.s. deviation of the epitope residues was calculated. To remove outlier residues, the top and bottom 10% of the Cα deviations were removed from the r.m.s. deviation calculation. To calculate the volume overlap between a given antibody and the ligand-free trimer structure, the alignment from above was used to compute the overlap volume between the antibody from the complex structure and the ligand-free trimer structure with the phase_volCalc utility from Schrödinger (http://www.schrodinger.com/). An antibody epitope was considered to be present in the ligand-free trimer structure if at least 70% of the epitope residues as defined by the antibody-antigen complex structure were also present in the ligand-free trimer structure. For mapping the per-residue r.m.s. deviation computation onto the ligand-free trimer structure, residues part of any antibody epitope (including epitopes with less than 70% total residues present) were included in the analysis; if a given residue was part of more than one antibody epitope, the highest r.m.s. deviation value for that residue among all epitopes was used. Antibody-volume-overlap values were mapped onto the ligand-free trimer structure for all residues part of the epitope for the given antibody; if a residue was part of more than one antibody epitope, then the lowest volume overlap for that residue among all epitopes was used. Correlations of structural properties with neutralization and/or binding data were computed with the Spearman correlation coefficient with two-tailed P values.
